Yvonne Greenstreet Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

Yvonne Greenstreet is Chief Executive Officer of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 81,526 shares of ALNY, which is worth approximately $20.4 Million. The most recent transaction as insider was on Feb 14, 2025, when has been sold 1,213 shares (Common Stock) at a price of $258.13 per share, resulting in proceeds of $313,111. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 81.5K

11.01% 3M change

80.61% 12M change

Total Value Held $20.4 Million

Yvonne Greenstreet Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 14 2025	SELL Open market or private sale	$313,111 $258.13 p/Share	1,213 Reduced 1.47%	81,526 Common Stock
Feb 13 2025	BUY Grant, award, or other acquisition	-	3,859 Added 4.46%	82,739 Common Stock
Nov 26 2024	SELL Open market or private sale	$1,306,576 $250.35 p/Share	5,219 Reduced 6.21%	78,880 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	-	10,658 Added 11.25%	84,099 Common Stock
Aug 20 2024	SELL Open market or private sale	$4,200,000 $280.0 p/Share	15,000 Reduced 16.96%	73,441 Common Stock
Aug 20 2024	BUY Exercise of conversion of derivative security	$1,275,000 $85.0 p/Share	15,000 Added 14.5%	88,441 Common Stock
Aug 01 2024	SELL Open market or private sale	$4,089,960 $270.0 p/Share	15,148 Reduced 17.1%	73,441 Common Stock
Aug 01 2024	BUY Exercise of conversion of derivative security	$1,287,580 $85.0 p/Share	15,148 Added 14.6%	88,589 Common Stock
Jul 11 2024	SELL Open market or private sale	$1,851,273 $261.0 p/Share	7,093 Reduced 8.81%	73,441 Common Stock
Jun 25 2024	SELL Open market or private sale	$1,904,415 $229.42 p/Share	8,301 Reduced 9.34%	80,534 Common Stock
Jun 24 2024	BUY Grant, award, or other acquisition	-	16,953 Added 16.03%	88,835 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	23,754 Added 24.84%	71,882 Common Stock
Feb 28 2024	SELL Open market or private sale	$458,418 $156.35 p/Share	2,932 Reduced 5.74%	48,128 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	-	5,921 Added 10.39%	51,060 Common Stock
Feb 16 2024	SELL Open market or private sale	$1,042,267 $148.26 p/Share	7,030 Reduced 13.48%	45,139 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	16,953 Added 24.53%	52,169 Common Stock
Aug 04 2023	SELL Open market or private sale	$758,456 $186.95 p/Share	4,057 Reduced 10.33%	35,216 Common Stock
Aug 03 2023	BUY Grant, award, or other acquisition	-	8,941 Added 18.54%	39,273 Common Stock
Apr 27 2023	SELL Open market or private sale	$1,484,620 $194.96 p/Share	7,615 Reduced 20.07%	30,332 Common Stock
Apr 26 2023	BUY Grant, award, or other acquisition	-	16,952 Added 30.88%	37,947 Common Stock
Aug 04 2022	SELL Payment of exercise price or tax liability	$1,229,930 $204.92 p/Share	6,002 Reduced 22.23%	20,995 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	13,095 Added 32.66%	26,997 Common Stock
Dec 22 2021	SELL Payment of exercise price or tax liability	$479,377 $188.88 p/Share	2,538 Reduced 15.44%	13,902 Common Stock
Dec 21 2021	BUY Grant, award, or other acquisition	-	5,417 Added 24.78%	16,440 Common Stock
Aug 06 2021	SELL Open market or private sale	$10,559,736 $199.0 p/Share	53,064 Reduced 82.8%	11,023 Common Stock

Also insider at

PCRX

Pacira BioSciences, Inc. Healthcare

Director